Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
Bibliographic record
Abstract
5563 Background: ctDNA is a promising biomarker for predicting disease progression, survival, and surgical outcomes in patients with solid tumors. In a phase 1 study (NCT03564691), ILT4 inhibitor MK-4830 + pembro had a manageable safety profile and showed antitumor activity in pts with solid tumors. We present results from a global, randomized phase 2 study (NCT05446870) evaluating quantitative change in ctDNA in pts with high-grade serous ovarian cancer (HGSOC) who received neoadjuvant pembro + chemo ± MK-4830. Methods: Eligible pts were female, aged ≥18 y, with previously untreated histologically confirmed FIGO stage 3 or 4 HGSOC and an ECOG performance status of 0 or 1, and were candidates for interval debulking surgery. Pts were randomly assigned 1:1 to receive neoadjuvant MK-4830 800 mg + pembro 200 mg + chemo (paclitaxel 175 mg/m 2 and carboplatin AUC 5-6) (arm 1) or pembro + chemo (arm 2) IV Q3W for 3 cycles. Pts underwent interval debulking surgery followed by 3 cycles of adjuvant therapy with the neoadjuvant regimen; adjuvant bevacizumab IV Q3W was permitted. ctDNA was assessed at each cycle using the Signatera assay (Natera, Inc.). A constrained longitudinal data analysis model was used to estimate the posterior probability that the coefficient for treatment assignment was <0, evaluating whether the reduction in ctDNA from cycle 1 (C1) was larger in arm 1. The primary end point was change in ctDNA from C1 at C3 in pts with detectable ctDNA; safety was a secondary end point. Results: At data cutoff (Dec 20, 2023), 160 pts were enrolled; 159 pts received treatment (arm 1, n = 79; arm 2, n = 80). Median study follow-up was 8.3 months (range, 1.9-16.4) in arm 1 and 8.3 months (range, 2.1-16.3) in arm 2. Median age was 61.5 y in both arms. 64 pts (80.0%) in arm 1 and 68 pts (85.0%) in arm 2 had available ctDNA data at C1; 51 pts (63.8%) and 63 pts (78.8%), respectively, had available ctDNA data at C3. Median ratio of ctDNA C3 to C1 was 0.02 (range, 0-1.53) in arm 1 and 0.01 (range, 0-0.60) in arm 2. The posterior probability that the coefficient for treatment assignment was <0 in the model was 38.8%, indicating a low posterior certainty of larger ctDNA reduction in arm 1. AEs occurred in 75 pts (94.9%) in arm 1 and all pts (100%) in arm 2. TRAEs occurred in 74 pts (93.7%) in arm 1 and in 79 pts (98.8%) in arm 2; grade 3-5 events occurred in 37 pts (46.8%) and 44 pts (55.0%), respectively. TRAEs led to death in 2 pts in arm 1; no treatment-related deaths occurred in arm 2. Conclusions: In pts with HGSOC, reductions in ctDNA were similar between neoadjuvant/adjuvant MK-4830 + pembro + chemo vs pembro + chemo. Real-time tumor-informed ctDNA testing may be feasibly incorporated into future clinical trials as a surrogate outcome to evaluate response. The safety profile of MK-4830 + pembro + chemo was comparable to pembro + chemo. Clinical trial information: NCT05446870 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".